These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21288101)

  • 1. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Siasos G; Tousoulis D; Stefanadis C
    N Engl J Med; 2011 Feb; 364(5):481-2. PubMed ID: 21288101
    [No Abstract]   [Full Text] [Related]  

  • 2. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Geisler T; Bigalke B; Schwab M
    N Engl J Med; 2011 Feb; 364(5):481; author reply 482. PubMed ID: 21288102
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis.
    Liu YP; Hao PP; Zhang MX; Zhang C; Gao F; Zhang Y; Chen YG
    Thromb Res; 2011 Dec; 128(6):593-4. PubMed ID: 21794898
    [No Abstract]   [Full Text] [Related]  

  • 4. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
    Peters BJ; Harmsze AM; ten Berg JM; Maitland-van der Zee AH; Tjoeng MM; de Boer A; Deneer VH
    Pharmacogenomics; 2011 Feb; 12(2):141-4. PubMed ID: 21332306
    [No Abstract]   [Full Text] [Related]  

  • 5. Current status of clopidogrel pharmacogenomics.
    Giusti B; Gori AM; Marcucci R; Abbate R
    Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
    [No Abstract]   [Full Text] [Related]  

  • 6. Clopidogrel in acute coronary syndrome: to genotype or not?
    Storey RF
    Lancet; 2009 Jan; 373(9660):276-8. PubMed ID: 19108882
    [No Abstract]   [Full Text] [Related]  

  • 7. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.
    Frére C; Cuisset T; Gaborit B; Alessi MC; Hulot JS
    J Thromb Haemost; 2009 Aug; 7(8):1409-11. PubMed ID: 19496924
    [No Abstract]   [Full Text] [Related]  

  • 8. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
    Scott SA; Sangkuhl K; Gardner EE; Stein CM; Hulot JS; Johnson JA; Roden DM; Klein TE; Shuldiner AR;
    Clin Pharmacol Ther; 2011 Aug; 90(2):328-32. PubMed ID: 21716271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects.
    Fontana P; Hulot JS; De Moerloose P; Gaussem P
    J Thromb Haemost; 2007 Oct; 5(10):2153-5. PubMed ID: 17697139
    [No Abstract]   [Full Text] [Related]  

  • 12. Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome.
    Brackbill ML; Kidd RS; Abdoo AD; Warner JG; Harralson AF
    Heart Vessels; 2009 Mar; 24(2):73-8. PubMed ID: 19337788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.
    Fuster V; Sweeny JM
    JAMA; 2010 Oct; 304(16):1839-40. PubMed ID: 20978263
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
    Paré G; Mehta SR; Yusuf S; Anand SS; Connolly SJ; Hirsh J; Simonsen K; Bhatt DL; Fox KA; Eikelboom JW
    N Engl J Med; 2010 Oct; 363(18):1704-14. PubMed ID: 20979470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of CYP2C19 *2 and *17 genotyping in clinical practice. Promising but not ready yet.
    Bergmeijer TO; ten Berg JM
    Rev Esp Cardiol (Engl Ed); 2012 Mar; 65(3):205-7. PubMed ID: 22284726
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors associated with clopidogrel nonresponsiveness.
    Momary KM; Dorsch MP
    Future Cardiol; 2010 Mar; 6(2):195-210. PubMed ID: 20230261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.
    Tello-Montoliu A; Jover E; Marín F; Bernal A; Lozano ML; Sánchez-Vega B; Pastor FJ; Hurtado JA; Valdés M; Vicente V; Rivera J
    Rev Esp Cardiol (Engl Ed); 2012 Mar; 65(3):219-26. PubMed ID: 22116003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a CYP2C19 genotyping assay for clinical use.
    Cervinski MA; Schwab MC; Lefferts JA; Lewis LD; Lebel KA; Tyropolis AM; Pflueger SM; Tsongalis GJ
    Am J Clin Pathol; 2013 Feb; 139(2):202-7. PubMed ID: 23355205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.
    Beitelshees AL; Horenstein RB; Vesely MR; Mehra MR; Shuldiner AR
    Clin Pharmacol Ther; 2011 Mar; 89(3):455-9. PubMed ID: 21270785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.